A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

Monjuvi shows real-world effectiveness in relapsed/refractory DLBCL, with 11.3 months PFS and 24.8 months OS. Second-line Monjuvi treatment yields higher ORR (78.5%) compared to third-line (62.8%).

Lymphoma originates in lymphocytes and is classified into Hodgkin and Non-Hodgkin types, each with unique features and treatment approaches. Early-stage lymphoma is localized, often with a high cure ...

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester ...

Please provide your email address to receive an email when new articles are posted on . Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world ...

Four symptoms may indicate a possible relapse of diffuse large B-cell lymphoma. Learn more about them and when to contact a doctor. A relapse of diffuse large B-cell lymphoma can cause a variety of ...

The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...

Incyte said on Monday its experimental combo therapy met the main goal in a late-stage trial testing patients with a type of blood cancer. The trial tested a combination of tafasitamab, lenalidomide ...